Raphael Pharmaceutical (RAPH) Receivables (2024 - 2025)
Raphael Pharmaceutical (RAPH) posted Receivables of $2000.0 for Q4 2025, little changed sequentially from $2000.0 in Q4 2024, and little changed YoY from $2000.0 in Q4 2024.
Raphael Pharmaceutical (RAPH) Receivables (2024 - 2025) Analysis & Trends
Raphael Pharmaceutical has reported Receivables for 2 years, with the latest figure at $2000.0 in Q4 2025.
- Quarterly Receivables changed 0.0% year-over-year to $2000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $2000.0, changed 0.0% from the prior year.
- Receivables was little changed at $2000.0 in Q4 2025 per RAPH's latest filing, from $2000.0 in the prior quarter.
- Over five years, Receivables peaked at $2000.0 in Q4 2024 and troughed at $2000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 3.07 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 3.49 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 1.57 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 5.84 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 310.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 3.67 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 887.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.15 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 1.08 Bn |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |